NDLI: A zsírmáj és a globális kardiometabolikus kockázat.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Szollár, Lajos
Description	Author Affiliation: Szollár L ( Semmelweis Egyetem, Általános Orvostudományi Kar Kórélettani Intézet Budapest Nagyvárad tér 4. 1089. szollaj@net.sote.hu)
Abstract	Non-alcoholic fatty liver disease (NAFLD) can be found in approximately 30% of adults in industrialized societies. Non-alcoholic steatohepatitis (NASH) is its most severe histological form and progresses to cirrhosis in 20% of these patients. Once developed, 30% to 40% of patients with cirrhosis will suffer liver-related death. NAFLD is considered the hepatic manifestation of the metabolic syndrome. Recent findings linking the components of metabolic syndrome with NAFLD and the progression to nonalcoholic steatohepatitis will be reviewed; in particular, the role of visceral adipose tissue, insulin resistance, adipocytokines, oxidative stress and diminished antioxidants within the liver in the exacerbation of these conditions. It is now widely accepted that non-hepatic mechanisms are largely responsible for the development of insulin resistance, which causes hepatic steatosis. Insulin resistance, a key feature of metabolic syndrome, is crucial for NASH development. We have a classical chicken-egg problem: insulin resistance causes hepatic steatosis or vice-versa? A possible sequence of the pathogenetic events is the following: increased free fatty acid supply - increased de novo lipogenesis - triglyceride and VLDL overproduction - atherogenic dyslipidemia- oxidative stress (lipid oxidation and peroxidation) - exhaustion of antioxidant defense system- 'Tsunami' of inflammatory cytokines- fibrosis- carcinogenesis. Given the strong association of NAFLD with metabolic syndrome, early recognition, assessment and management are essential. The management emphasizes weight reduction and attention to global cardiometabolic risk factors, similar to recommendations for management of the elements of metabolic syndrome.
File Format	HTM / HTML
ISSN	00306002
e-ISSN	17886120
Journal	Orvosi Hetilap
Issue Number	47
Volume Number	151
Language	Hungarian
Publisher	Markusovszky Lajos
Publisher Date	2010-11-21
Publisher Place	Hungary
Access Restriction	Open
Subject Keyword	Cardiovascular Diseases Risk Assessment Complications Risk Factors Insulin Resistance Metabolic Syndrome X Liver Cirrhosis Metabolism Liver Neoplasms Disease Progression Fatty Liver Pathology Etiology Cell Transformation, Neoplastic Discipline Medicine Lipid Peroxidation
Alternative Title	Fatty liver and global cardiometabolic risk
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat.

A zsírmáj szerepe a metabolikus szindróma kialakulásában.

A steatosis kialakulásának patomechanizmusai.

Nem alkoholos zsírmáj és zsírmájhepatitis.

Inzulinrezisztencia és pubertás kapcsolata megnövekedett kardiometabolikus kockázatú gyermekekben.

Nem alkoholos zsírmáj és hepatocellularis carcinoma - 2016.

A metabolikus szindrómától a kardiometabolikus kockázat fogalmáig.

A hepatitis C-vírus-fertôzés és hepatocarcinogenesis.

A hepatitis C, a diabetes mellitus és a steatosis hepatis kapcsolatának néhány klinikai vonatkozása.

A zsírmáj és a globális kardiometabolikus kockázat.

Similar Documents

A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat.

A zsírmáj szerepe a metabolikus szindróma kialakulásában.

A steatosis kialakulásának patomechanizmusai.

Nem alkoholos zsírmáj és zsírmájhepatitis.

Inzulinrezisztencia és pubertás kapcsolata megnövekedett kardiometabolikus kockázatú gyermekekben.

Nem alkoholos zsírmáj és hepatocellularis carcinoma - 2016.

A metabolikus szindrómától a kardiometabolikus kockázat fogalmáig.

A hepatitis C-vírus-fertôzés és hepatocarcinogenesis.

A hepatitis C, a diabetes mellitus és a steatosis hepatis kapcsolatának néhány klinikai vonatkozása.

A zsírmáj és a globális kardiometabolikus kockázat.